^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Invasive Breast Cancer: HER-2 negative...Useful in Certain Circumstances…Bevacizumab…
Source:
Excerpt:
HER2 Negative Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE (IV) M1 DISEASE…HER2-Negative…Useful in Certain Circumstances...Paclitaxel/bevacizumab
Secondary therapy:
bisphosphonate bound paclitaxel
Source:
Title:
98P - Final results from AVANTI, a multicentre German observational study of 1st-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC) (ID 141)
Published date:
05/03/2021
Excerpt:
Eligible pts had HER2-negative aBC...eligible pts at 346 centres received ≥1 dose of BEV with PAC (n=1821) or CAP (n=295)...Overall (complete or partial) response rate was 49% (95% CI 46–51%). Median PFS was 12.6 (95% CI 11.9–13.2) mo (12.8 with BEV + PAC, 10.5 with BEV + CAP); median OS was 23.9 (22.2–25.1) mo.
Secondary therapy:
paclitaxel; capecitabine
Trial ID:
Source:
Title:
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
Excerpt:
...histological-proven, HER-2 negative measurable stage IV disease; 4....
Trial ID:
Source:
Title:
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Excerpt:
...- HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;...
Trial ID:
More C2 evidence
Source:
Title:
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Excerpt:
...- HER2-negative metastatic breast cancer...
Trial ID:
Source:
Title:
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Excerpt:
...- primary HER2-negative operable breast cancer;...
Trial ID:
Source:
Title:
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
Excerpt:
...- Patients must have pathologically confirmed ER, PR and HER2/neu negative (FISH ratio of 4 weeks from their most recent chemotherapy or radiation therapy treatment....
Trial ID:
Source:
Title:
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Excerpt:
...- All tumors must be ER-, PR- and HER2-negative...
Trial ID:
Source:
Title:
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Excerpt:
...- Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease....
Trial ID:
Source:
Title:
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Excerpt:
...- HER2-negative disease (as defined by fluorescence in situ hybridization [FISH])...
Trial ID:
Source:
Title:
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
Excerpt:
...- Patients with histologically or cytologically confirmed, HER2-negative, metastatic Breast Cancer...
Trial ID:
Source:
Title:
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Excerpt:
...- HER-2 negative disease....
Trial ID:
Source:
Title:
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
Excerpt:
...- HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0, 1+ or 2+ and fluorescent in situ hybridization (FISH)...
Trial ID:
Source:
Title:
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy
Excerpt:
...- histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v....
Trial ID:
Source:
Title:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Excerpt:
...- Histologically confirmed HER2-negative breast cancer...
Trial ID:
Source:
Title:
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Excerpt:
...HER2-negative breast cancer patients confirmed by immunohistochemical test or fluorescent in situ hybridization(FISH); 4....
Trial ID:
Source:
Title:
Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
Excerpt:
...- HER2 negative disease;...
Trial ID:
Source:
Title:
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
Excerpt:
...- HER2-negative disease...
Trial ID:
Source:
Title:
Prospective, multicenter, single-arm clinical study of chemotherapy combined with bevacizumab neoadjuvant therapy for early or locally advanced HER2-negative breast cancer
Excerpt:
...Histopathological diagnosis of HER2-negative invasive breast cancer (including triple negative breast cancer; Or ER/PR positive and HER2 negative); -- HER2 negative was defined as 0/1+ on standard immunohistochemical (IHC) test; In ISH, HER2/CEP17 ratio was less than 2.0 or HER2 gene copy number was less than 4. ...
Trial ID:
Source:
Title:
A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer
Excerpt:
...Histologically or cytologically confirmed, HER2-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy. ...
Trial ID:
Source:
Title:
“An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in combination with bevacizumab, and second line treatment of patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer”
Excerpt:
...Patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer, who are candidates for chemotherapy. ...
Trial ID:
Source:
Title:
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study)
Excerpt:
...- Patients with histologically or cytologically confirmed, HER2/neu-negative, pre- or postmenopausal adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy. ...
Trial ID:
Source:
Title:
A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in the primary tumors with reference to the obtained responses in patients with large primary HER2 negative breast cancers.
Excerpt:
...Histologically or cytologically confirmed, HER2-negative, men or pre- or post-menopausal women with primary operable adenocarcinoma of the breast, more than 2.0 cm in size 5. ...
Trial ID:
Source:
Title:
Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy
Excerpt:
...- Female Patients with histologically diagnosed hormone receptor positive (ER and/or PR positive ), HER2/neu negative (IHC 1,500/µl, platelets >1000,000/ µl and Hb ≥8 g/dl(iv) Normal or reduced renal function but no necessity for dialysis2. ...
Trial ID:
Source:
Title:
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Excerpt:
...Written informed consent (informed consent document to be approved by the Independent Ethics Committee [IEC]) obtained prior to any study-specific procedureAge ﾳ18 yearsAble to comply with the protocolHistologically or cytologically confirmed, HER2-negative, pre- or post-menopausal women with adenocarcinoma of the breast with measurable or non-measurable LR or metastatic disease, who are candidates for chemotherapy. ...
Trial ID:
Source:
Title:
A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on objective response rate in patients with Metastatic Breast Cancer
Excerpt:
...Signed informed consent (informed consent document to be approved by the Independent Ethics Committee) obtained prior to initiation of any study-specific procedure or treatment as confirmation of the patients awareness and willingness to comply with the study requirements Age ≥18 years Able to comply with the protocol Histologically or cytologically confirmed and documented metastatic breast cancer women, proven HER2-negativity (secondary lesion or primitive tumor), who are candidates for chemotherapy Lesions not amenable to curative surgery or radiotherapy. ...
Trial ID:
Source:
Title:
A multicenter, placebo-controlled, double-blind randomised phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by six cycles of docetaxel, doxorubucin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer.
Excerpt:
...1.Female patient > 18 years2.Histologically or cytologically proven adenocarcinoma of the breast 3.Stage II (minimum tumor size > 3 cm) or Stage III disease (except inflammatory breast cancer), as defined by the AJCC Staging Manual, 6th Edition, 20024.HER2-negative disease (as defined by fluorescence in situ hybridization [FISH])5.ECOG performance status 0-16.No prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive breast cancer7.Normal cardiac function (ejection fraction > lower limit of normal) as determined by MUGA or echocardiogram8.If female of childbearing potential, pregnancy test is negative and willing to use effective contraception while on treatment and for at least 3 months after the last dose of study therapy9.Patient is accessible and willing to comply with treatment and follow-up10.Patient is willing to provide written informed consent prior to the performance of any study-related procedures11.Required laboratory valuesa.Absolute neutrophil count > 1.5 x 109/Lb.Hemoglobin > 9.0 g/dLc.Platelet count > 100 x 109/Ld.Creatinine < 1.5 mg/dLe.Total bilirubin < 1.0 x upper limit of normal (ULN)f.Alkaline phosphatase and AST/ALT within the following parameters. ...
Trial ID:
Source:
Title:
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Excerpt:
...- Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with locally recurrent or metastatic disease, suitable for chemotherapy....
Trial ID:
Source:
Title:
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Excerpt:
...- Patients must be either HER2-negative or HER2-positive and...
Trial ID:
Source:
Title:
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Excerpt:
...- HER2-negative, locally advanced (stage II or III) or inflammatory cancer of the breast;...
Trial ID:
Source:
Title:
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Excerpt:
...- stage IV, HER2 negative metastatic breast cancer;...
Trial ID:
Source:
Title:
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
Excerpt:
...- Confirmed HER2/neu-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy....
Trial ID:
Source:
Title:
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
Excerpt:
...- Histologically confirmed breast adenocarcinoma, metastatic (measurable or unmeasurable lesion), HER2 negative (on the last tumor tissue analyzed), Patient to receive first-line chemotherapy paclitaxel and bevacizumab in a weekly manner as recommended by the EMEA....
Trial ID:
Source:
Title:
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
Excerpt:
...- Pathologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of the breast, T2-T3 / T4a-c / N0-2 / M0, with positive estrogen and/or progesterone receptors, and Her-2-neu negative....
Trial ID:
Source:
Title:
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Excerpt:
...Signed the informed consent and volunteered to join the study with good compliance; 3, histopathologically confirmed HER2-negative invasive breast cancer (including triple-negative breast cancer; Or Luminal breast cancer, that is, ER/PR positive and HER2 negative) :...
Trial ID:
Source:
Title:
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Excerpt:
...- The breast cancer must be HER2-negative based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer....
Trial ID:
Source:
Title:
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
Excerpt:
...- Locally recurrent or metastatic Her2-negative breast cancer...
Trial ID:
Source:
Title:
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Excerpt:
...- Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past...
Trial ID:
Source:
Title:
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
Excerpt:
...By pathologic evaluation, primary tumor must be T1-4N1-3M0 or T3-4N 0M0 that is ER/PR positive or negative and HER-2/neu negative (1+) immunocytochemistry or...
Trial ID:
Source:
Title:
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Excerpt:
...Patients with HER2-negative disease evaluated by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH)/Chromogenic in situ hybridisation (CISH) (IHC 0 or 1+, or 2+ and negative FISH)....
Trial ID:
Source:
Title:
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Excerpt:
...Women with previously untreated metastatic breast cancer, ER/PR/HER2/neu negative....
Trial ID:
Source:
Title:
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Excerpt:
...- Histologically or cytologically confirmed, HER2-negative, men or pre- or post-menopausal women with primary operable adenocarcinoma of the breast, greater than or equal to (>=) 2.5 centimeters (cm) in size...
Trial ID:
Source:
Title:
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
Excerpt:
...HER2 negative disease (IHC 0/1+ or 2+ with FISH negative) 4....
Trial ID:
Source:
Title:
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Excerpt:
...- HER2-negative disease, by fluorescence in situ hybridization...
Trial ID:
Source:
Title:
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Excerpt:
...To determine progression-free survival among women receiving bevacizumab + ABI-007 given as second-line combination therapy for hormone receptive negative, Her-2 negative metastatic breast cancer....
Trial ID:
Source:
Title:
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
Excerpt:
...- Participants with HER2-negative metastatic breast cancer....
Trial ID:
Source:
Title:
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Excerpt:
...Histologically or cytologically confirmed, HER2-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy....
Trial ID:
Source:
Title:
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Excerpt:
...- Participants must have histologically or cytologically confirmed HER2 negative invasive breast adenocarcinoma....
Trial ID:
Source:
Title:
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
Excerpt:
...- HER2-negative (HER2 0 or 1+, or HER2 2+ by IHC if FISH-negative allowed)...
Trial ID:
Source:
Title:
TC Avastin. ICORG 08-10, V6
Excerpt:
...Patients must have disease which is HER2 negative (0, or 1+ by immunohistochemistry (IHC) or fluorescence in situ hybridization FISH non amplified) 4....
Trial ID:
Source:
Title:
Metronomic Therapy in Metastatic Breast Cancer.
Excerpt:
...- HER2-negative disease...
Trial ID:
Source:
Title:
A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Excerpt:
...Clinically and / or radiologically proven stage IV or recurrent HER2 negative breast cancer....
Trial ID:
Source:
Title:
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
Excerpt:
...- HER2 negative disease (IHC 0/1+, IHC 2+ and/or FISH negative)...
Trial ID:
Source:
Title:
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Excerpt:
...Pathologically confirmed HER2/neu-negative, ER/PR positive inoperable or metastatic adenocarcinoma of the breast 4....
Trial ID:
Source:
Title:
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
Excerpt:
...- HER2/neu-negative patients with metastasis diagnosed 6 or more months after completing primary systemic treatment (neoadjuvant, adjuvant chemotherapy)....
Trial ID:
Source:
Title:
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Excerpt:
...- HER2-negative breast cancer patients...
Trial ID:
Source:
Title:
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Excerpt:
...- ErbB2-negative disease by immunohistochemistry (negative or 1+) or fluorescent in situ hybridization (FISH)...
Trial ID:
Source:
Title:
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
Excerpt:
...- HER2 negative...
Trial ID:
Source:
Title:
Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer
Excerpt:
...- Estrogen receptor-, progesterone receptor-, and HER2-negative by immunohistochemistry (IHC) 0 or 1+ OR fluorescence in situ hybridization negative (in case IHC is 2+)...
Trial ID:
Source:
Title:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Excerpt:
...- HER2-negative metastatic breast cancer...
Trial ID:
Less C2 evidence
Source:
Title:
401P - Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial
Published date:
10/16/2023
Excerpt:
CNS-ORR, CNS-CBR, ORR, CBR were 73% (8/11), 82% (9/11), 27% (3/11) and 55% (6/11), respectively, including a pt with PR for 8 cycles....Utidelone in combination with etoposide and bevacizumab has shown anti-tumor activity and manageable toxicity in breast cancer pts with brain metastasis, and a randomized control trial is warrantied.
Secondary therapy:
etoposide IV + UTD1
Source:
Title:
Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
Published date:
02/08/2023
Excerpt:
8 RCTs were finally included in this study, including 2470 patients with HER2-negative metastatic breast cancer….However, the subgroup analysis showed that the combination of bevacizumab and capecitabine demonstrated a more significant significance than bevacizumab or chemotherapy alone (subgroup 1: MD = 10.11, 95% CI (7.88, 12.34), P = 0.00)....The combination therapy of bevacizumab and capecitabine can significantly improve the RDP and OSR of patients compared with the control group.
Secondary therapy:
capecitabine
DOI:
10.1155/2023/8740221
Source:
Title:
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
Published date:
02/17/2022
Excerpt:
Patients with human epidermal growth factor receptor 2 (HER2)-negative mBC treated with front-line BEV in combination with chemotherapy were eligible....The median PFS and the median overall survival (OS) were 13.3 (95% CI: 11.7-14.8) and 32.3 months (95% CI: 27.7-36.9), respectively. Maintenance therapy, with hormonal agents (ET) and/or BEV, was associated with longer OS versus no maintenance therapy (47.2 versus 23.6 months; p < 0.001) in patients with hormone receptor (HR)-positive disease and BEV maintenance offered longer OS versus no maintenance in patients with HR-negative disease (52.8 versus 23.3; p = 0.023).
Secondary therapy:
Chemotherapy
DOI:
10.3390/curroncol29020105
Source:
Title:
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
Published date:
12/20/2021
Excerpt:
Immunohistochemistry (IHC) analysis was applied to investigate and compare the vascular normalization and anti-angiogenic effects of two commonly used anti-angiogenic agents, Sunitinib and Bevacizumab, administered prior to chemotherapy in HER2-negative breast cancer patients....Both drugs when combined with chemotherapy resulted in significant decline in tumor proliferation after C1 and C4 (baseline vs post-C4 Ki67 index p = 0.006 for Sunitinib vs p = 0.021 for Bevacizumab).
DOI:
10.1007/s10549-021-06470-7
Trial ID:
Source:
Title:
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
Published date:
11/02/2021
Excerpt:
CONTRADICTING EVIDENCE: We retrospectively analyzed patients with HER2-ABC who received 1LCT between January 2011 and December 2016 in three participating institutions....In the shorter TTF group, OS of patients who received paclitaxel plus bevacizumab (PB) therapy was significantly inferior to that of those who received chemotherapy other than PB (HR 2.57, P < 0.001, log-rank)...
Secondary therapy:
paclitaxel
DOI:
10.1038/s41598-021-00711-x
Source:
Title:
Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project
Published date:
09/15/2021
Excerpt:
...overall survival (OS) with paclitaxel plus bevacizumab or paclitaxel alone as first-line treatment in patients with HER2-negative metastatic breast cancer (MBC). In the original analysis, the OS adjusted for major factors was significantly longer with paclitaxel and bevacizumab than with paclitaxel alone.
Secondary therapy:
paclitaxel
DOI:
10.1371/journal.pone.0255017
Source:
Title:
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
Published date:
02/15/2021
Excerpt:
The results of this study suggest that second-line therapy with bevacizumab in combination with eribulin has a meaningful clinical activity and may represent a potential therapeutic option for patients with HER2-negative MBC.
Secondary therapy:
eribulin mesylate
DOI:
10.1016/j.esmoop.2021.100054
Source:
Title:
Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance
Published date:
07/05/2020
Excerpt:
Network meta-analysis for pathological complete response (pCR) revealed Addition of targeted therapies especially Trastuzumab for HER2+ breast cancer and Bevacizumab for HER2- breast cancer along with Anthracyclines and/or Taxanes based chemotherapy significantly improves pCR but with increased haematological toxicities.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.critrevonc.2020.103015
Source:
Title:
Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy
Excerpt:
The efficacy of paclitaxel and bevacizumab (PB)...PB improved the overall response rate and time to treatment failure in patients with HER2- advanced breast cancer and improved overall survival in some patient subgroups.
Secondary therapy:
paclitaxel
DOI:
10.21873/invivo.11917
Source:
Title:
Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer
Excerpt:
Bevacizumab combined with docetaxel has more excellent efficacy than docetaxel alone in the treatment of HER-2-negative recurrent metastatic breast cancer, and it prolongs the survival of patients, with tolerable adverse reactions, which is worthy of further clinical application.
Secondary therapy:
docetaxel
Source:
Title:
Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis
Excerpt:
Both for patients with HER2-positive and negative metastatic breast cancer, docetaxel and bevacizumab with or without trastuzumab as first-line treatment resulted in long survival, especially in terms of progression-free survival.
Secondary therapy:
docetaxel
DOI:
10.26355/eurrev_202109_26643
